Vestipitant

Vestipitant
(IUPAC) ime
	(2S)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methylpiperazine-1-carboxamide
Klinički podaci
Identifikatori
CAS broj	334476-64-1
ATC kod	nije dodeljen
PubChem	9832383
Hemijski podaci
Formula	C23H21F10N3O
Mol. masa	545.416 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C23H21F10N3O/c1-12(13-7-14(21(25,26)27)9-15(8-13)22(28,29)30)35(2)20(37)36-6-5-34-11-19(36)17-4-3-16(24)10-18(17)23(31,32)33/h3-4,7-10,12,19,34H,5-6,11H2,1-2H3 ; Key: FRBNMOFIMDUNIJ-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

Vestipitant je razvio GlaksoSmitKlajn. Ovaj lek deluje kao selektivni antagonist za NK₁ receptor. On je u razvoju kao potencijalni antiemetik i anksiolitik^[3]^[4], i kao lek za tinitus.^[5]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Reddy, GK; Gralla, RJ; Hesketh, PJ (2006). „Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis”. Supportive cancer therapy 3 (3): 140–2. DOI:10.3816/SCT.2006.n.011. PMID 18632487.
↑ Brocco, M; Dekeyne, A; Mannoury La Cour, C; Touzard, M; Girardon, S; Veiga, S; De Nanteuil, G; Dejong, TR i dr.. (2008). „Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents”. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 18 (10): 729–50. DOI:10.1016/j.euroneuro.2008.06.002. PMID 18657401.
↑ Clinical Trials NCT00394056 Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss

	Portal Medicina
	Portal Hemija